trending Market Intelligence /marketintelligence/en/news-insights/trending/UaCx7VsCIcmNYKLioMw-NA2 content esgSubNav
In This List

Sanofi's $2.5B acquisition of I-O company Synthorx gets antitrust clearance

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Sanofi's $2.5B acquisition of I-O company Synthorx gets antitrust clearance

Sanofi's $2.5 billion acquisition of immuno-oncology company Synthorx Inc. received antitrust clearance.

The Paris-based drugmaker said the waiting period under the Hart-Scott-Rodino Act applicable to the deal has expired.

On Dec. 23, 2019, Sanofi started a tender offer to acquire all of Synthorx's shares at $68 each.

La Jolla, Calif.-based Synthorx is developing therapies intended to treat cancer and autoimmune disorders through its proprietary technology. The company's lead asset, THOR-707, is being evaluated as a potential treatment of multiple solid tumor types as a stand-alone therapy and in combination with immune checkpoint inhibitors.